This morning, Supernus announced it received FDA approval for Oxtellar XR, its extended-release (ER) formulation of the anti-epilepsy drug oxcarbazepine. According to officials at Supernus, they believe the label points to clear differentiation on tolerability versus the predecessor immediate release (IR) oxcarbazepine. With two FDA-approved products on the market by mid-2013 (the company will launch ER topiramate product Trokendi XR by mid-year 2013.

Authored By: 
Joseph I. Sirven MD
Authored Date: